Evonile Pharma’s ₹860 rights issue, covering the 5:12 entitlement, recent losses, share price performance and debt reduction.
Evonile Pharma Ltd is coming out with its Rights Issue (RI) of 10287832 equity shares of Rs. 5 each at a fixed price of Rs. 860 per share to mobilize Rs. 884.75 cr.
The RI opens for subscription on November 19, 2026, and will close on December 03, 2026.
The company is offering RI in the ratio of 5 for 12 to its eligible stakeholders as of the record date of November 11, 2026.
The company is asking for Rs. 645 per share on application for number of shares applied. The rest Rs. 215 per share will be payable by first and final call as decided by the board of directors.
Post allotment, RI shares will be listed on BSE and NSE.
The company is spending Rs. 0.54 cr. for this RI process, from the net proceeds, Rs. 800 cr. for repayment/prepayment of certain borrowings, and Rs. 79.40 cr. for general corporate purposes.
The RI is solely lead managed by the company itself, and MUFG Intime India Pvt. Ltd. is the registrar to the issue.
Post-RI, company’s current paid-up equity capital of Rs. 12.35 cr. (24690797 equity shares) will stand enhanced to Rs. 17.49 cr. (34978629 shares).
Based on the RI pricing, the company is looking for a market cap of Rs. 3008.16 cr.
Financial Performance
On the financial performance front, for the last two fiscals, the company has posted total income/ net profit, – (loss), of Rs. 398.236 cr. / Rs. 100.90 cr. (FY25), Rs. 393.10 cr. / Rs. 93.18 cr. (FY26).
For H1 of FY27, it posted a loss of Rs. – (45.33) cr. on a total income of Rs. 176.34 cr., that raises eyebrows.
Its NAV stood at Rs. 312.55 as of March 31, 2026.
About Company
Evonile Pharma Ltd., (EPL) erstwhile known as Novartis India Ltd., is a pure-play medicines company.
The Company is focused on four core therapeutic areas: cardiovascular-renal-metabolic, immunology, neuroscience and oncology.
In addition to two established technology platforms (chemistry and biotherapeutics), three emerging platforms (gene & cell therapy, radioligand therapy and xRNA) are added for continued investment into R&D and manufacturing scale.
Its brands hold key positions in therapeutic areas, such as, Voveran, which is the brand for bone and pain; Simulect, Certican, Sandimmun, Neoral, and Myfortic, which is the brand for transplantation immunology; and Tegrital and Exelon, which is the brand for neurosciences.
Guided by strong ethical standards, regulatory compliance, and meaningful engagement with healthcare professionals, the company strives to expand access to established therapies while creating lasting value for patients, partners, and the healthcare community.
It drives sustainable enterprise growth by strengthening its core therapeutic segments, deepening scientific engagement with healthcare professionals, and continuously expanding market access to deliver long-term value in India.
The offer document is silent on its employees’ strength data.
Scrip Performance: Based on BSE Website Data: Scrip Code: 500672 (FV Rs. 5).
The scrip last closed on cum-right basis at Rs. 1861.50 on November 09, 2026, and opened on an ex-right basis at Rs. 1586.00 on November 11, 2026.
Since then, it has marked a high/low of Rs. 1626.75 / Rs. 1461.05.
The scrip last closed at Rs. 1464.90 as of November 17, 2026. For the last 52 weeks’ it has posted a high/low of Rs. 2179.10 / Rs. 631.50.
The promoters’ holding has been at 0%L for the last quarter ended on June 30, 2026.
The counter is trading well above the RI price, with vested interest operators. The RI is at a discount of 41.29% based on its last traded price.
Dividend Policy
The company has paid dividends of Rs. 25 per share for FY24 and FY25, and skipped for FY26.
It will adopt a prudent dividend policy, based on its financial performance and future prospects.
Rights Issue Summary
- The company is engaged in manufacturing and developing medicines for core therapeutic areas.
- The company posted declining trends in its top and bottom lines for FY25 and FY26.
- It marked losses for H1-FY27, that remains major concern.
- The RI is priced at a discount of around 41%.
- Well-informed investors may park moderate funds for long term.
Conclusion
EPL is engaged in manufacturing and developing medicines for core therapeutic areas. The company posted declining trends in its top and bottom lines for FY25 and FY26.
It marked losses for H1-FY27, that remains major concern. The RI is priced at a discount of around 41%.
As major funds will be used to reduce its debt, saving on finance cost will help it to stage noteworthy financial performance. Well-informed investors may park moderate funds for long term.
Disclaimer
No financial information whatsoever published anywhere here should be construed as an offer to buy or sell securities, or as advice to do so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions. Readers must consult a qualified financial advisor before making any actual investment decisions, based on the information published here. Any reader taking decisions based on any information published here does so entirely at their own risk. Investors should bear in mind that any investment in stock markets is subject to unpredictable market-related risks. The above information is based on RHP and other documents available as of date coupled with market perception. The author has no plans to invest in this offer.
(SEBI registered Research Analyst-Mumbai).